GO:0070667 negative regulation of mast cell proliferation: Signaling Checkpoints, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070667 describes any biological process that stops, prevents, or reduces the rate or extent of mast cell proliferation.
• The inhibitory Fc receptor FcgammaRIIB is a canonical negative regulator of mast cell proliferation, acting by recruiting SHIP and dampening c-kit and IgE receptor signaling [1,8].
• The Src-family kinase Lyn is a key negative regulator of mast cell proliferation, and loss of Lyn leads to hyperproliferation and myeloproliferative disease in mice.
• Mast cell homeostasis is also modulated by microgravity, miR-490-5p, and the tumor microenvironment, linking this GO term to immune dysfunction and cancer [4,6,7].
• Dysregulation of negative regulation of mast cell proliferation contributes to mastocytosis, allergic inflammation, and tumor-associated mast cell expansion [1,4,5].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal role of candidate genes in this process [1,5,8].
Description
Mast cells are tissue-resident immune cells that play central roles in allergic reactions, host defense, and tissue remodeling. Their proliferation must be tightly controlled to prevent pathological accumulation. GO:0070667, negative regulation of mast cell proliferation, encompasses any process that stops, prevents, or reduces the rate or extent of mast cell proliferation. This term is critical for understanding how the immune system maintains homeostasis and how its failure contributes to disease. The inhibitory receptor FcgammaRIIB was among the first molecules shown to negatively regulate mast cell proliferation by recruiting the inositol phosphatase SHIP and opposing c-kit-mediated growth signals [1,8]. Subsequent work identified the Src-family kinase Lyn as a negative regulator, as Lyn-deficient mast cells hyperproliferate and mice develop myeloproliferative disease. More recent studies have implicated microRNAs, such as miR-490-5p, and environmental factors like simulated microgravity in modulating mast cell homeostasis [6,7]. In cancer, single-cell and spatial transcriptomics have revealed mast-cell heterogeneity and arginine-metabolism-associated markers in breast cancer, suggesting that negative regulation of mast cell proliferation may influence tumor progression. Understanding the molecular players and signaling checkpoints that enforce this negative regulation is essential for developing therapies for mastocytosis, allergic diseases, and cancer.
negative regulation of mast cell proliferation At A Glance
| GO ID | GO:0070667 |
|---|---|
| GO term | negative regulation of mast cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of mast cell proliferation, down-regulation of mast cell proliferation, downregulation of mast cell proliferation, inhibition of mast cell proliferation |
| Major function | Stops, prevents, or reduces the rate or extent of mast cell proliferation |
| Key regulators | FcgammaRIIB, Lyn, SHIP, miR-490-5p |
| Associated diseases | Mastocytosis, allergic inflammation, cancer |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, single-cell RNA-seq |
What Is GO:0070667?
GO:0070667, negative regulation of mast cell proliferation, is defined as any biological process that stops, prevents, or reduces the rate or extent of mast cell proliferation. This includes receptor-mediated inhibitory signaling, intracellular phosphatases, kinases, and microRNAs that dampen mitogenic pathways in mast cells. The term is a biological process and is distinct from positive regulation or general regulation of mast cell proliferation.
Why Is negative regulation of mast cell proliferation Important in Cell Biology?
Negative regulation of mast cell proliferation is essential for immune homeostasis and prevention of mast cell neoplasms. Dysregulation of this process can lead to mastocytosis, severe allergic reactions, and tumor-associated mast cell expansion, making it a critical area of research for immunology and oncology [1,4,5].
• Prevents pathological mast cell accumulation in tissues.
• Controls allergic and anaphylactic responses by limiting mast cell numbers.
• Loss of negative regulators like Lyn leads to myeloproliferative disease.
• FcgammaRIIB deficiency exacerbates mast cell hyperproliferation [1,8].
• MicroRNAs such as miR-490-5p modulate mast cell proliferation in irritable bowel syndrome.
• Simulated microgravity disrupts mast cell homeostasis, highlighting environmental regulation.
• Mast cell heterogeneity in breast cancer may involve altered negative regulation.
• Targeting negative regulators could offer therapeutic strategies for mastocytosis.
• CRISPR screens can identify novel negative regulators of mast cell proliferation.
• Understanding this process aids in designing mast cell-targeted therapies.
What Happens During negative regulation of mast cell proliferation?
Inhibitory Receptor Engagement
In simple terms: Inhibitory receptors on the mast cell surface act like brakes that stop growth signals.
The inhibitory Fc receptor FcgammaRIIB is a key negative regulator of mast cell proliferation. When co-ligated with the high-affinity IgE receptor or c-kit, FcgammaRIIB recruits the inositol phosphatase SHIP, which hydrolyzes phosphatidylinositol 3,4,5-trisphosphate and dampens downstream survival and proliferation signals [1,8]. This mechanism prevents excessive mast cell expansion in response to antigen or stem cell factor.
Kinase-Mediated Checkpoints
In simple terms: Certain kinases act as brakes by phosphorylating inhibitory targets.
The Src-family kinase Lyn is a negative regulator of mast cell proliferation. Lyn-deficient mast cells exhibit hyperproliferation and increased sensitivity to growth factors, and Lyn-/- mice develop myeloproliferative disease. Lyn exerts its inhibitory effects by phosphorylating immunoreceptor tyrosine-based inhibitory motifs and activating phosphatases that terminate proliferative signals.
MicroRNA Regulation
In simple terms: Small RNA molecules can fine-tune mast cell growth by targeting messenger RNAs.
MicroRNA miR-490-5p has been implicated in mast cell regulation in irritable bowel syndrome. Its expression modulates mast cell proliferation and activation, suggesting that microRNAs contribute to the negative regulation of mast cell proliferation.
Environmental and Metabolic Modulation
In simple terms: External factors like gravity and metabolism can influence how fast mast cells divide.
Simulated microgravity has detrimental effects on mast cell homeostasis and function, altering proliferation rates. Additionally, single-cell and spatial transcriptomics in breast cancer have revealed mast-cell heterogeneity and arginine-metabolism-associated markers, indicating that metabolic cues may influence negative regulation of mast cell proliferation in the tumor microenvironment.
Key Genes Involved in GO:0070667 negative regulation of mast cell proliferation
The following genes and proteins are experimentally implicated in the negative regulation of mast cell proliferation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCGR2B | Inhibitory Fc receptor; recruits SHIP to dampen proliferation | Knockout mice show enhanced mast cell proliferation [1,8] |
| LYN | Src-family kinase; negative regulator of mast cell proliferation | Lyn-/- mice develop myeloproliferative disease |
| INPP5D (SHIP) | Inositol phosphatase; hydrolyzes PIP3 to terminate growth signals | Mediates FcgammaRIIB inhibitory signaling [1,8] |
| KIT | Receptor tyrosine kinase; positive regulator opposed by negative signals | c-kit-mediated proliferation is inhibited by FcgammaRIIB |
| MIR490 | MicroRNA; modulates mast cell proliferation | Implicated in irritable bowel syndrome |
| CHMP4C | Involved in necroptosis regulation; potential link to mast cell biology | Studied in pancreatic cancer progression |
| RIPK1 | Kinase in necroptosis pathway; may influence mast cell survival | Studied in pancreatic cancer |
| RIPK3 | Kinase in necroptosis pathway; may influence mast cell survival | Studied in pancreatic cancer |
| MLKL | Executioner of necroptosis; may influence mast cell survival | Studied in pancreatic cancer |
| Autophagy-related genes | Modulate keratinocyte and fibroblast activation; may affect mast cell microenvironment | Studied in wound healing |
| Arginine metabolism genes | Associated with mast-cell heterogeneity in breast cancer | Identified by single-cell and spatial transcriptomics |
| FcεRI | High-affinity IgE receptor; co-ligation with FcgammaRIIB inhibits proliferation | Key to allergic responses |
| SHIP1 | Phosphatase; negative regulator of mast cell proliferation | Downstream of FcgammaRIIB [1,8] |
| SHP-1 | Phosphatase; potential negative regulator | May be recruited by inhibitory receptors |
| CBL | E3 ubiquitin ligase; may downregulate growth factor receptors | Potential negative regulator |
| miR-490-5p | MicroRNA; modulates mast cell proliferation | Linked to irritable bowel syndrome |
How Is negative regulation of mast cell proliferation Regulated?
The negative regulation of mast cell proliferation is itself regulated by the balance between activating and inhibitory signals. FcgammaRIIB expression and function are modulated by cytokines and antigen exposure. Lyn activity is controlled by phosphorylation and dephosphorylation events. MicroRNAs such as miR-490-5p are regulated transcriptionally and post-transcriptionally. Environmental factors like microgravity can alter mast cell homeostasis. In cancer, metabolic cues such as arginine availability may influence mast cell proliferation.
negative regulation of mast cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCGR2B | Mastocytosis, allergic inflammation | Fcgr2b knockout mouse; mast cell-specific deletion [1,8] |
| LYN | Myeloproliferative disease | Lyn knockout mouse |
| MIR490 | Irritable bowel syndrome | miR-490-5p mimic/inhibitor in mast cells |
| KIT | Mastocytosis, cancer | Kit D816V knock-in mouse |
| CHMP4C | Pancreatic cancer progression | CHMP4C knockout in pancreatic cancer cells |
Mastocytosis and Myeloproliferative Disorders
Loss of negative regulation of mast cell proliferation contributes to mastocytosis and myeloproliferative diseases. Lyn-deficient mice develop myeloproliferative disease characterized by mast cell hyperproliferation. FcgammaRIIB deficiency also leads to enhanced mast cell proliferation, suggesting that defects in inhibitory signaling can drive pathological mast cell accumulation [1,8].
Allergic Inflammation and Irritable Bowel Syndrome
Dysregulated mast cell proliferation is associated with allergic inflammation and irritable bowel syndrome. miR-490-5p, which modulates mast cell proliferation, has been implicated in irritable bowel syndrome pathogenesis. Inhibitory receptors like FcgammaRIIB help limit mast cell expansion during allergic responses.
Cancer and Tumor Microenvironment
Mast cells can promote or inhibit tumor progression depending on context. Single-cell and spatial transcriptomics in breast cancer have revealed mast-cell heterogeneity and arginine-metabolism-associated markers, suggesting that negative regulation of mast cell proliferation may be altered in the tumor microenvironment. Additionally, pathways such as necroptosis (RIPK1/RIPK3/MLKL) and autophagy may influence mast cell survival and proliferation in cancer [2,3].
From negative regulation of mast cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FcgammaRIIB negatively regulate mast cell proliferation? | Fcgr2b knockout mouse and mast cell-specific deletion [1,8] |
| Is Lyn a negative regulator of mast cell proliferation? | Lyn knockout mouse |
| What is the role of miR-490-5p in mast cell proliferation? | miR-490-5p overexpression and inhibition in mast cells |
| How does simulated microgravity affect mast cell homeostasis? | Mast cells cultured under simulated microgravity |
| What genes are associated with mast-cell heterogeneity in breast cancer? | Single-cell and spatial transcriptomics of breast cancer samples |
| Does CHMP4C regulate necroptosis in pancreatic cancer? | CHMP4C knockout and overexpression in pancreatic cancer cell lines |
How to Study the negative regulation of mast cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function of candidate genes | Test if Fcgr2b or Lyn is required for negative regulation [1,5] |
| Point mutation knock-in | Effect of specific mutations | Model Kit D816V in mastocytosis |
| Overexpression | Gain-of-function | Overexpress miR-490-5p to assess proliferation |
| Single-cell RNA-seq | Transcriptomic heterogeneity | Identify mast cell subsets in breast cancer |
| Spatial transcriptomics | Spatial gene expression | Map mast cells in tumor microenvironment |
| Proliferation assay | Cell division rate | Quantify effects of genetic manipulations [1,5] |
| Flow cytometry | Surface marker expression | Assess FcgammaRIIB and c-kit levels [1,8] |
| Western blot | Protein expression and phosphorylation | Measure Lyn activity and SHIP recruitment |
Genetic Knockout and Knock-in Models
CRISPR/Cas9-mediated knockout of candidate genes such as Fcgr2b or Lyn in mast cells or mouse models is essential to establish causality in negative regulation of mast cell proliferation [1,5,8]. Knock-in of point mutations, such as Kit D816V, can model disease-associated variants.
Transcriptomic and Single-Cell Approaches
Single-cell RNA sequencing and spatial transcriptomics have been used to dissect mast-cell heterogeneity and identify arginine-metabolism-associated markers in breast cancer, providing insights into how negative regulation may be altered in disease.
MicroRNA and Epigenetic Studies
Overexpression or inhibition of microRNAs such as miR-490-5p in mast cells can reveal their role in modulating proliferation. Epigenetic profiling may identify additional regulators.
Functional Proliferation Assays
Mast cell proliferation is typically measured by thymidine incorporation, CFSE dilution, or MTT assays. These assays are used to quantify the effects of genetic manipulations on negative regulation [1,5].
How CRISPR Can Be Used to Study GO:0070667 negative regulation of mast cell proliferation
Knockout
CRISPR knockout of Fcgr2b or Lyn in mast cells or mouse models can confirm their role as negative regulators of mast cell proliferation. For example, Lyn-/- mast cells hyperproliferate, demonstrating that Lyn is a negative regulator. Fcgr2b knockout enhances mast cell proliferation in response to c-kit signaling [1,8].
Point Mutation
Point mutation knock-in can model disease-associated variants. For instance, the Kit D816V mutation is associated with mastocytosis and can be introduced using CRISPR to study its effects on negative regulation.
Knock-in
Knock-in of tagged proteins, such as GFP-tagged SHIP, allows visualization of inhibitory signaling complexes in live mast cells. This can reveal how FcgammaRIIB recruits SHIP to dampen proliferation [1,8].
Overexpression
Overexpression of negative regulators like FcgammaRIIB or miR-490-5p can suppress mast cell proliferation, providing gain-of-function evidence. This approach is useful for validating therapeutic targets [1,7].
How EDITGENE Supports negative regulation of mast cell proliferation Research
Researchers studying negative regulation of mast cell proliferation-related genes often need to determine whether a candidate gene is causally involved in suppressing mast cell growth. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mast cell proliferation research.
Frequently Asked Questions About negative regulation of mast cell proliferation
What is GO:0070667?
GO:0070667 is the Gene Ontology term for negative regulation of mast cell proliferation, defined as any process that stops, prevents, or reduces the rate or extent of mast cell proliferation.
What genes are involved in negative regulation of mast cell proliferation?
Key genes include FCGR2B, LYN, INPP5D (SHIP), KIT, and MIR490, among others [1,5,7,8].
How does FcgammaRIIB inhibit mast cell proliferation?
FcgammaRIIB recruits the phosphatase SHIP upon co-ligation with activating receptors, which hydrolyzes PIP3 and dampens proliferative signals [1,8].
What is the role of Lyn in mast cell proliferation?
Lyn is a Src-family kinase that acts as a negative regulator; Lyn-deficient mast cells hyperproliferate and mice develop myeloproliferative disease.
Can microgravity affect mast cell proliferation?
Yes, simulated microgravity has detrimental effects on mast cell homeostasis and function, including proliferation.
What diseases are associated with defective negative regulation of mast cell proliferation?
Mastocytosis, allergic inflammation, irritable bowel syndrome, and certain cancers have been linked to dysregulated mast cell proliferation [1,4,5,7].
How can CRISPR be used to study negative regulation of mast cell proliferation?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of candidate genes in mast cell proliferation [1,5,8].
What is the link between miR-490-5p and mast cells?
miR-490-5p modulates mast cell proliferation and has been implicated in irritable bowel syndrome.
Are there single-cell studies on mast cells in cancer?
Yes, single-cell and spatial transcriptomics have revealed mast-cell heterogeneity and arginine-metabolism-associated markers in breast cancer.
What model systems are used to study negative regulation of mast cell proliferation?
Common models include knockout mice (e.g., Lyn-/-, Fcgr2b-/-), mast cell lines, and primary mast cells [1,5,8].
Conclusion
Negative regulation of mast cell proliferation (GO:0070667) is a critical biological process that prevents pathological mast cell accumulation. Key regulators such as FcgammaRIIB, Lyn, and miR-490-5p have been identified through decades of research [1,5,7,8]. Dysregulation of this process contributes to mastocytosis, allergic diseases, and cancer, making it a promising therapeutic target [1,4,5]. Advances in CRISPR gene editing and single-cell technologies are poised to uncover new regulators and translate these findings into clinical applications [4,5].
References
- 1. Malbec O et al.. 2002. Negative regulation of mast cell proliferation by FcgammaRIIB.. Mol Immunol 38(16-18):1295-9 PMID: 12217398
- 2. Qiang L et al.. 2021. Keratinocyte autophagy enables the activation of keratinocytes and fibroblastsand facilitates wound healing.. Autophagy 17(9):2128-2143 PMID: 32866426
- 3. Yu L et al.. 2025. CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway.. J Adv Res 77:653-668 PMID: 39870301
- 4. Gao M et al.. 2026. Integrating single-cell and spatial transcriptomics to dissect mast-cell heterogeneity and arginine-metabolism-associated markers in BRCA.. Neoplasia 73:101281 PMID: 41655499
- 5. Hernandez-Hansen V et al.. 2004. The Src kinase Lyn is a negative regulator of mast cell proliferation.. J Leukoc Biol 75(1):143-51 PMID: 14525964
- 6. Kim M et al.. 2022. Detrimental effects of simulated microgravity on mast cell homeostasis and function.. Front Immunol 13:1055531 PMID: 36591304
- 7. Ren HX et al.. 2017. Role of mast cell-miR-490-5p in irritable bowel syndrome.. World J Gastroenterol 23(1):93-102 PMID: 28104984
- 8. Malbec O et al.. 1999. Negative regulation of c-kit-mediated cell proliferation by Fc gamma RIIB.. J Immunol 162(8):4424-9 PMID: 10201978
